Navamedic ASA: Q1 2017 results
Oslo, 10 May 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 78.2 million in the first quarter of 2017 (NOK 60.8 million in Q1 2016), representing a growth of 28.6%, in part due to a widened distribution across new European markets under the partnership with TopRidge Pharma. The Sippi® commercialisation continues to be on a good track and the company expects to enter an accelerated growth path towards the long-term revenue potential of the proprietary urine measurement system. "Navamedic had a solid first quarter in 2017, with overall revenues up 28.6 percent compared to the